Table 1

Effect of huRANKL treatment of C4-2 cells on bone morphometry

BV/TV (%)

TuV/TV (%)

Tb.Th. (μm)

Tb.N. (mm-1)

Tb.Sp. (μm)

Ob.Pm./B.Pm. (%)

N.Oc./BS (#/mm)


Control

5.88 ± 0.99

80.48 ± 2.49

31.58 ± 4.83

2.03 ± 0.42

597.24 ± 215.70

5.23 ± 1.03

4.06 ± 0.37

Prevention

6.65 ± 2.31

78.69 ± 2.06

34.27 ± 2.05

1.84 ± 0.50

690.77 ± 188.80

9.51 ± 1.76a

4.37 ± 0.71

Treatment

6.75 ± 1.72

77.85 ± 2.99

36.00 ± 4.80

1.79 ± 0.37

633.46 ± 193.00

8.35 ± 2.66

6.32 ± 0.50b


Bone histomorphometric analysis was performed in the area adjacent to the growth plate (0.525–1.225 mm below the growth plate: site of injection, n = 4 in control and treatment animals; n = 5 in prevention animals. Two animals were removed from the analysis due to sectioning difficulties. Results are expressed as mean ± SE. Statistical significance was evaluated using student's paired t test. a Control vs. prevention (p < 0.05). b Control vs. treatment (p < 0.05). Abbreviations: %BV/TV, percentage bone volume in tissue volume; %TuV/TV, tumor volume in tissue volume as a percentage; Tb.Th., trabecular thickness in μm; Tb.N., trabecular number per mm; Tb.Sp., trabecular seperation in μm; Ob.Pm./B.Pm., osteoblast perimeter to bone perimeter; N.Oc./BS, ratio of osteoclast number to bone surface.

Morrissey et al. BMC Cancer 2007 7:148   doi:10.1186/1471-2407-7-148

Open Data